Market Place
Sourcing Support
Celltrion Launches AVTOZMA Subcutaneous in U.S
16 Mar 2026 //
PR NEWSWIRE
Celltrion Spotlights Abpro`s ABP-102 at 44th JPM Conference
15 Jan 2026 //
GLOBENEWSWIRE
Celltrion Unveils Pipeline, US R&D Expansion at JPM Conference
13 Jan 2026 //
PR NEWSWIRE
Abpro & Celltrion Gain FDA Clearance For Cancer Antibody ABP-102
06 Jan 2026 //
GLOBENEWSWIRE
Celltrion`s Steqeyma Autoinjector Gets Positive CHMP Opinion
18 Dec 2025 //
PHARMIWEB
Abpro Holdings Submits IND For Phase 1 Trial Of T Cell Engager
15 Dec 2025 //
GLOBENEWSWIRE
Celltrion Launches Fda-Approved 300Mg OMLYCLO Biosimilar
02 Dec 2025 //
PR NEWSWIRE
Celltrion receives Canada approval for Eydenzelt
27 Nov 2025 //
BUSINESSWIRE
Celltrion Publishes Liberty-Cd Study Analysis on Zymfentra
26 Nov 2025 //
PR NEWSWIRE
Celltrion Looks Beyond Biosims With $350M Antibody Deal Option
19 Nov 2025 //
FIERCE BIOTECH
EC Approves Remsima IV: World`s First Liquid Infliximab
18 Nov 2025 //
BUSINESSWIRE
Abpro, Celltrion To Showcase Next-Gen HER2×CD3 T-Cell Engager
04 Nov 2025 //
GLOBENEWSWIRE
Kaigene Licenses KG006 And KG002 Exclusively To Celltrion
04 Nov 2025 //
PR NEWSWIRE
FDA Grants Interchangeability To Celltrion`s Denosumab
30 Oct 2025 //
PR NEWSWIRE
Regeneron, Celltrion Shake Hands On Eylea Biosimilar Settlement
22 Oct 2025 //
FIERCE PHARMA
FDA Approves Expanded Pediatric Indications for Yuflyma
17 Oct 2025 //
PR NEWSWIRE
Celltrion`s EYDENZELT® FDA Approved As EYLEA® Biosimilar
09 Oct 2025 //
PR NEWSWIRE
Hikma And Celltrion Enhance Biosimilar Access In MENA Region
06 Oct 2025 //
PHARMAWEB
Celltrion launches AVTOZMA (IV) Formulation In US
02 Oct 2025 //
PR NEWSWIRE
Health Canada Approves Celltrion`s Stoboclo & Osenvelt Biosimilar
19 Sep 2025 //
PHARMAWEB
Celltrion Launches Omlyclo™ in Europe at EADV 2025
18 Sep 2025 //
PHARMAWEB
FDA Greenlights Expanded Use of Celltrion`s Avtozma
11 Aug 2025 //
CONTRACTPHARMA
FDA Expands Indication for Avtozma in Cytokine Release Syndrome
07 Aug 2025 //
PR NEWSWIRE
Celltrion USA Debuts Denosumab Biosimilars in the U.S.
08 Jul 2025 //
CONTRACTPHARMA
Celltrion USA launches Denosumab biosimilars Stoboclo & Osenvelt
07 Jul 2025 //
PR NEWSWIRE
Celltrion Gets FDA Approval for more Steqeyma Dosing Options
15 Jun 2025 //
PR NEWSWIRE
Celltrion`s Yuflyma gets FDA interchangeability for all forms
23 May 2025 //
PR NEWSWIRE
Celltrion`s Yufyma Gets FDA interchangeability for All forms
21 May 2025 //
PR NEWSWIRE
Abpro, Celltrion reveal data for ABP-102/CT-P72 at AACR 2025
27 Apr 2025 //
GLOBENEWSWIRE
Celltrion`s YUFLYMA approved as biosimilar to Humira
15 Apr 2025 //
CONTRACTPHARMA
Celltrion`s STEQEYMA® (ustekinumab-stba) in Costco Program
27 Mar 2025 //
PR NEWSWIRE
Celltrion`s Remdantry™, formerly Inflectra®, available in Canada
27 Mar 2025 //
BUSINESSWIRE
Steqeyma, A Stelara Biosimilar, Now Available In The US
12 Mar 2025 //
PR NEWSWIRE
Celltrion`s Infliximab, First Monoclonal Antibody Biosimilar
11 Mar 2025 //
BUSINESSWIRE
FDA Approves First Omalizumab Biosimilar
10 Mar 2025 //
PR NEWSWIRE
FDA Approves Omlyclo As First Interchangeable Xolair Biosimilar
09 Mar 2025 //
PR NEWSWIRE
Celltrion receives FDA approval for Stoboclo & Osenvelt
04 Mar 2025 //
PR NEWSWIRE
Celltrion Gets EC Approval For Avtozma, Biosimilar To RoActemra
23 Feb 2025 //
BUSINESSWIRE
Celltrion Unveils LIBERTY Post-Hoc Analyses At 20th ECCO Congress
20 Feb 2025 //
BUSINESSWIRE
Celltrion Expands EU Biosimilar Portfolio With Two New Approvals
18 Feb 2025 //
BUSINESSWIRE
FDA approves Celltrion`s Avtozma, a biosimilar to Actemra
04 Feb 2025 //
PR NEWSWIRE
Amgen fends off Celltrion`s proposed Prolia biosim until June
29 Jan 2025 //
FIERCE PHARMA
FDA approves Celltrion`s Steqeyma, a biosimilar to Stelara
18 Dec 2024 //
PRNEWSWIRE
Health Canada Approves Celltrion’s Omlyclo™ Biosimilar (CT-P39)
09 Dec 2024 //
BUSINESSWIRE
Celltrion Presents Phase III Data for CT-41 & CT-P47 Biosimilars
18 Nov 2024 //
PR NEWSWIRE
Zymfentra® Coverage Increases with Top 3 PBM Partnership
31 Oct 2024 //
PR NEWSWIRE
Celltrion Presents Analysis Of Liberty Studies For Zymfentra®
29 Oct 2024 //
PR NEWSWIRE
Celltrion Presents 2-Year Findings For Infliximab (CT-P13 SC) In IBD
15 Oct 2024 //
BUSINESSWIRE
EC Approves Celltrion`s SteQeyma For Multiple Inflammatory Diseases
26 Aug 2024 //
BUSINESSWIRE
Celltrion`s Humira Biosimilar Added To Costco Prescription Program
12 Aug 2024 //
PR NEWSWIRE
Health Canada Approves Celltrion`s Steqeyma® For Inflammatory Conditions
01 Aug 2024 //
BUSINESSWIRE
EC approves Celltrion’s Omlyclo for allergic conditions
24 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Celltrion Omlyclo® Ec Approval: First Omalizumab Biosimilar In Europe
23 May 2024 //
BUSINESSWIRE
Celltrion HUMIRA Biosimilar At Low Wholesale Acquisition Cost
09 May 2024 //
PR NEWSWIRE
Celltrion USA completes submission of BLA to U.S. FDA for CT-P39
10 Mar 2024 //
PR NEWSWIRE
Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC)
23 Feb 2024 //
BUSINESSWIRE
Celltrion USA completes submission of Biologics License Application for CT-P47
28 Jan 2024 //
PR NEWSWIRE
Newly spun-off WuXi XDC locks up ADC deal with Korea`s Celltrion
24 Jan 2024 //
FIERCE PHARMA
Data Presented Support the Potential of Celltrion’s Infliximab CT-P13
16 Oct 2023 //
BUSINESSWIRE
Celltrion Celebrates a Decade of Biosimilar Innovation in Europe
10 Sep 2023 //
BUSINESSWIRE
